mk-7655 and nitrocefin

Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen's intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic interventions. Here we report a prospective advance in the treatment of M. abscessus infection; increasing the susceptibility of the organism to amoxicillin, by repurposing the β-lactamase inhibitor, relebactam, in combination with the front line M. abscessus drug imipenem. We establish by multiple in vitro methods that this combination works synergistically to inhibit M. abscessus. We also show the direct competitive inhibition of the M. abscessus β-lactamase, Bla

Topics: Amoxicillin; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Imipenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Plasmids